SG11201603193PA - Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide - Google Patents

Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Info

Publication number
SG11201603193PA
SG11201603193PA SG11201603193PA SG11201603193PA SG11201603193PA SG 11201603193P A SG11201603193P A SG 11201603193PA SG 11201603193P A SG11201603193P A SG 11201603193PA SG 11201603193P A SG11201603193P A SG 11201603193PA SG 11201603193P A SG11201603193P A SG 11201603193PA
Authority
SG
Singapore
Prior art keywords
methods
binding polypeptide
immunosuppressive therapy
alpha beta
multiple administration
Prior art date
Application number
SG11201603193PA
Inventor
Gregor Blank
Rupert Handgretinger
Karin Schilbach
Gina Lacorcia
Daniel Snell
Andreas Menrad
Original Assignee
Genzyme Corp
Children S University Hospital Tübingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Children S University Hospital Tübingen filed Critical Genzyme Corp
Publication of SG11201603193PA publication Critical patent/SG11201603193PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
SG11201603193PA 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide SG11201603193PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897809P 2013-10-30 2013-10-30
PCT/US2014/063254 WO2015066379A2 (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Publications (1)

Publication Number Publication Date
SG11201603193PA true SG11201603193PA (en) 2016-05-30

Family

ID=52021413

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603193PA SG11201603193PA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
SG10201803473WA SG10201803473WA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201803473WA SG10201803473WA (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Country Status (8)

Country Link
US (2) US11142575B2 (en)
EP (1) EP3063174B1 (en)
CN (1) CN106795220A (en)
AU (2) AU2014342182B2 (en)
CA (1) CA2928756A1 (en)
MX (1) MX2016005687A (en)
SG (2) SG11201603193PA (en)
WO (1) WO2015066379A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11142575B2 (en) * 2013-10-30 2021-10-12 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
US20180298099A1 (en) * 2015-09-16 2018-10-18 Harry C. Ledebur, Jr. T-Cell Recepter (TCR) Targeting Therapies for Immune-Mediated Adverse Drug Reactions (ADRs) and Other Conditions
CN108070644B (en) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 Diagnosis system for gestational hypertension
JP2020530283A (en) * 2017-07-07 2020-10-22 ハンミ ファーマシューティカル カンパニー リミテッド New therapeutic enzyme fusion proteins and their uses
CN109777778B (en) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 Genetically modified gamma delta T cells
DE102017127984B4 (en) * 2017-11-27 2019-12-05 Immatics US, Inc. Method for the propagation and activation of γδ T cells
CA3135032A1 (en) * 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
EP4058483A4 (en) * 2019-11-14 2023-11-15 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN116234829A (en) * 2020-01-03 2023-06-06 马伦戈治疗公司 anti-TCR antibody molecules and uses thereof
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
DK2343320T3 (en) 2005-03-25 2018-01-29 Gitr Inc ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
EP2041180B8 (en) 2006-06-19 2014-03-05 Liquidating Trust Ilt3 binding molecules and uses therefor
JP2010515456A (en) 2007-01-09 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド SP35 antibody and use thereof
JP2012501178A (en) 2008-08-26 2012-01-19 マクロジェニクス，インコーポレーテッド T cell receptor antibody and method of use thereof
ES2895480T3 (en) 2010-03-04 2022-02-21 Macrogenics Inc Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
WO2012012737A2 (en) * 2010-07-23 2012-01-26 The University Of Toledo Stable tregs and related materials and methods
UY34317A (en) * 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
US11142575B2 (en) * 2013-10-30 2021-10-12 Genzyme Corporation Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide

Also Published As

Publication number Publication date
CA2928756A1 (en) 2015-05-07
EP3063174A2 (en) 2016-09-07
CN106795220A (en) 2017-05-31
US20220098299A1 (en) 2022-03-31
AU2014342182A1 (en) 2016-05-19
MX2016005687A (en) 2017-03-30
US11142575B2 (en) 2021-10-12
WO2015066379A2 (en) 2015-05-07
AU2014342182B2 (en) 2020-05-14
EP3063174B1 (en) 2020-12-09
AU2020217395A1 (en) 2020-09-03
SG10201803473WA (en) 2018-06-28
WO2015066379A3 (en) 2015-07-09
US20160244523A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
IL287516A (en) Therapeutic uses of empagliflozin
HRP20190101T1 (en) Therapeutic uses of empagliflozin
SG11201603193PA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
IL245744A0 (en) Therapeutic peptides
HK1219983A1 (en) Therapeutic peptides
HK1213818A1 (en) Therapeutic uses of empagliflozin
HK1214829A1 (en) Therapeutic peptides
RS58097B1 (en) Therapeutic uses of empagliflozin
EP2967709A4 (en) Therapeutic cryoablation system
HK1222324A1 (en) Stem cell composition for venous administration
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
GB201318686D0 (en) Pharmaceutical preparations
GB2531169B (en) Method for determining degree of modified potency of bipathic medicament
ZA201603463B (en) An inhalable medicament
GB201301721D0 (en) Pharmaceutical Preparations
IL245760A0 (en) An inhalable medicament
EP2968458A4 (en) Dosage regimen for therapeutic method
HUE037492T2 (en) Individual central administration of chipcards
GB201406511D0 (en) Support for therapeutic use
EP2996684A4 (en) Therapeutic methods